Education Library

Resources for Health Care Professionals





Italian Paper Evaluates Completeness of Revascularization in Complex CAD

March 1, 2021

Sergio Leonardi, MD, and Stefano De Servi, MD, discuss their paper evaluating completeness of revascularization in patients with complex, stable CAD who underwent PCI.

Impact of Impella® on Dissected Coronary Artery Hemodynamics

February 23, 2021

Kiyotake Ishikawa, MD, discusses his paper on the impact of Impella on dissected coronary artery hemodynamics in a porcine model.

Abstract Presentation Examining the Influence of Analytic Methodology on Clinical Outcomes

November 5, 2020

Jeffrey Moses, MD, presents an abstract investigating  the limitations of administrative databases and the potential to generate misleading or inconsistent conclusions. 

Intermediate-Term Left Ventricular Function Following Non-Emergent Impella Protected PCI: Restore EF Study

October 27, 2020

Mitul Patel, MD, shares intermediate-term results from RESTORE EF, a multicenter, prospective, observational, single-arm study that is still actively enrolling patients

Results From PROTECT III, the Largest Prospective Multi-Center Single-Arm Study

October 27, 2020

Jeffrey Moses, MD, presents results from PROTECT III, the largest prospective study of Impella for high-risk PCI in the real world.

Your Destination for TCT 2020 Event Resources

October 6, 2020

TCT Connect highlighted the benefits of a more complete revascularization with Impella heart pumps in high-risk PCI patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients.

The Impact of Extensive Revascularization in Protected PCI and Impella® Support in Cardiogenic Shock

August 27, 2020

Armin Klesius, MD, discusses R-IMP-IT results and the importance of this data in clinical practice with Cristina Aurigemma MD, Professor Francesco Burzotta, MD, and Professor Carlo Trani, MD.

What is the PROTECT Series?

August 25, 2020

The PROTECT Series of FDA clinical studies includes PROTECT I6, PROTECT II RCT2 (the only FDA randomized, controlled trial ever conducted for hemodynamically supported high-risk PCI), and PROTECT III. 

No Increase in Mortality in Impella®-Supported Nonemergent High-Risk PCI

May 29, 2020

No increase in mortality seen in patients undergoing nonemergent high-risk Protected PCI in recent paper by Samin Sharma, MD and colleagues.

Activating Cath Labs for Emergent Procedures Amid COVID-19: Best Practices for STEMI and RV Dysfunction

May 8, 2020

As emergent cath lab procedures resume amid COVID-19, Ehtisham Mahmud, MD, shares best practices for STEMI and William O’Neill, MD, discusses right ventricular dysfunction.

Management of Patients During COVID-19 Crisis: Focus on Cardiovascular Complications

April 13, 2020

Seth Bilazarian, MD provides updates on COVID-19 data and clinical experiences, focusing on management of cardiovascular complications in patients during the COVID-19 crisis. 

Amin et al. 

February 24, 2020

The objective of the analysis, as stated in Amin et al., was “to describe the trends in Impella® use; variation in Impella use and its outcomes over 13 years.

Bleeding and Vascular Complications: A Look at Impella® Data Over Time

February 3, 2020

Daniel Raess, MD, describes how Impella® bleeding and vascular complication data has evolved over time and how it compares to data for other forms of mechanical circulatory support.

Discover New Data on Protected PCI versus Bailout PCI

January 6, 2020

Alexander Truesdell, MD, discusses Protected PCI versus bailout PCI using data from the cVAD Study and the PROTECT III study. 

Amin Analysis: Review of Trends, Variation and Outcomes in Impella® Use

November 17, 2019

Seth Bilazarian, MD, reviews the shortcomings of the Amin, et al., analysis presented at AHA 2019.